Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Folate
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Neurological disorders=== Conversion of homocysteine to methionine requires folate and vitamin B<sub>12</sub>. Elevated plasma homocysteine and low folate are associated with cognitive impairment, dementia and [[Alzheimer's disease]].<ref>{{cite journal |vauthors=Shen L, Ji HF |title=Associations between Homocysteine, Folic Acid, Vitamin B12 and Alzheimer's Disease: Insights from Meta-Analyses |journal=J. Alzheimers Dis. |volume=46 |issue=3 |pages=777β90 |date=2015 |pmid=25854931 |doi=10.3233/JAD-150140}}</ref><ref name=Ford2012/> Supplementing the diet with folic acid and vitamin B<sub>12</sub> lowers plasma homocysteine.<ref name=Ford2012/> However, several reviews reported that supplementation with folic acid alone or in combination with other B vitamins did not prevent development of cognitive impairment nor slow cognitive decline.<ref name=Li2014>{{cite journal |vauthors=Li MM, Yu JT, Wang HF, Jiang T, Wang J, Meng XF, Tan CC, Wang C, Tan L |title=Efficacy of vitamins B supplementation on mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis |journal=Curr Alzheimer Res |volume=11 |issue=9 |pages=844β52 |date=2014 |pmid=25274113 }}</ref><ref name=Ford2012>{{cite journal |vauthors=Ford AH, Almeida OP |title=Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials |journal=J. Alzheimers Dis. |volume=29 |issue=1 |pages=133β49 |date=2012 |pmid=22232016 |doi=10.3233/JAD-2012-111739}}</ref><ref>{{cite journal |vauthors=Wald DS, Kasturiratne A, Simmonds M |title=Effect of folic acid, with or without other B vitamins, on cognitive decline: meta-analysis of randomized trials |journal=Am. J. Med. |volume=123 |issue=6 |pages=522β527.e2 |date=June 2010 |pmid=20569758 |doi=10.1016/j.amjmed.2010.01.017}}</ref> Relative risk of [[autism spectrum disorder]]s (ASDs) was reported reduced by 23% when the maternal diet was supplemented with folic acid during pregnancy. Subset analysis confirmed this among Asian, European and American populations.<ref>{{cite journal |vauthors=Wang M, Li K, Zhao D, Li L |title=The association between maternal use of folic acid supplements during pregnancy and risk of autism spectrum disorders in children: a meta-analysis |journal=Mol Autism |volume=8 |page=51 |date=2017 |pmid=29026508 |pmc=5625821 |doi=10.1186/s13229-017-0170-8 |doi-access=free }}</ref> Cerebral folate deficiency (CFD) has been associated with ASDs. The cerebral folate receptor alpha (FRΞ±) transports 5-methyltetrahydrofolate into the brain. One cause of CFD is autoantibodies that interfere with FRa, and FRa autoantibodies have been reported in ASDs. For individuals with ASD and CFD, meta-analysis reported improvements with treatment with [[folinic acid]], a 5-formyl derivative of [[tetrahydrofolic acid]], for core and associated ASD symptoms.<ref name="Rossignol2021">{{cite journal |vauthors=Rossignol DA, Frye RE |title=Cerebral folate deficiency, folate receptor alpha autoantibodies and leucovorin (folinic acid) treatment in autism spectrum disorders: A systematic review and meta-analysis |journal=J Pers Med |volume=11 |issue=11 |date=November 2021 |page=1141 |pmid=34834493 |pmc=8622150 |doi=10.3390/jpm11111141 |doi-access=free |url=}}</ref> Some evidence links a shortage of folate with [[clinical depression]].<ref name="dep_coppen">{{cite journal|vauthors=Coppen A, Bolander-Gouaille C|s2cid=4828454|title=Treatment of depression: time to consider folic acid and vitamin B12|journal=Journal of Psychopharmacology|volume=19|issue=1|pages=59β65|date=January 2005|pmid=15671130|doi=10.1177/0269881105048899}}</ref> An 2024 umbrella meta-analysis concluded that folate supplementation alleviates depression symptoms, while folate deficiency is associated with an increased risk of depression, suggesting folate as a beneficial [[Combination therapy|adjunctive]] treatment in managing depression.<ref>{{cite journal | vauthors = Gao S, Khalid A, Amini-Salehi E, Radkhah N, Jamilian P, Badpeyma M, Zarezadeh M | title = Folate supplementation as a beneficial add-on treatment in relieving depressive symptoms: A meta-analysis of meta-analyses | journal = Food Science & Nutrition | volume = 12 | issue = 6 | pages = 3806β3818 | date = June 2024 | pmid = 38873435 | pmc = 11167194 | doi = 10.1002/fsn3.4073 }}</ref> Other research also found a link between depression and low levels of folate.<ref>{{cite journal|vauthors=Gilbody S, Lewis S, Lightfoot T|title=Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review|journal=American Journal of Epidemiology|volume=165|issue=1|pages=1β13|date=January 2007|pmid=17074966|doi=10.1093/aje/kwj347|doi-access=free}}</ref><ref>{{cite journal|vauthors=Gilbody S, Lightfoot T, Sheldon T|title=Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity|journal=Journal of Epidemiology and Community Health|volume=61|issue=7|pages=631β7|date=July 2007|pmid=17568057|pmc=2465760|doi=10.1136/jech.2006.050385}}</ref> The exact mechanisms involved in the development of schizophrenia and depression are not entirely clear, but the bioactive folate, [[Levomefolic acid|methyltetrahydrofolate]] (5-MTHF), a direct target of methyl donors such as [[S-adenosyl methionine]] (SAMe), recycles the inactive [[dihydrobiopterin]] (BH<sub>2</sub>) into [[tetrahydrobiopterin]] (BH<sub>4</sub>), the necessary [[Cofactor (biochemistry)|cofactor]] in various steps of monoamine synthesis, including that of [[dopamine]] and [[serotonin]]. BH<sub>4</sub> serves a regulatory role in monoamine neurotransmission and is required to mediate the actions of most antidepressants.<ref>{{cite journal|vauthors=Krebs MO, Bellon A, Mainguy G, Jay TM, Frieling H|title=One-carbon metabolism and schizophrenia: current challenges and future directions|journal=Trends in Molecular Medicine|volume=15|issue=12|pages=562β70|date=December 2009|pmid=19896901|doi=10.1016/j.molmed.2009.10.001}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)